Patent intelligence · US
US 11903920
Cannabinoid formulation: production method and use
Cannabinoid formulation: production method and use
Patent details — US 11903920
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 20, 2024
- Expiration
- Feb 15, 2044
- Applicant
- CHIROSYN DISCOVERY TECHNOLOGIES INC.
- Claims
- 15
- CPC classes
- A61K, A61K31/05, A61K31/352, A61K31/658
Quick answer
US 11903920 (Cannabinoid formulation: production method and use) is held by CHIROSYN DISCOVERY TECHNOLOGIES INC.. Status: granted. Granted Feb 20, 2024. Expires Feb 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CHIROSYN DISCOVERY TECHNOLOGIES INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/05, A61K31/352, A61K31/658, A61K45/06, A61K47/44
More from CHIROSYN DISCOVERY TECHNOLOGIES INC.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 11903920?
US 11903920 (Cannabinoid formulation: production method and use) is held by CHIROSYN DISCOVERY TECHNOLOGIES INC.. Status: granted. Granted Feb 20, 2024. Expires Feb 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11903920?
CHIROSYN DISCOVERY TECHNOLOGIES INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 11903920 expire?
Our index shows an expiration date of Feb 15, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.